Extending Progression-Free Survival: Osimertinib as First Line Treatment for Lung Cancer
Receiving a non-small cell lung cancer (NSCLC) diagnosis is overwhelming. Learning your tumor has a specific EGFR mutation adds another layer of complexity. Standard chemotherapy often brings heavy physical tolls. It also lacks the precision needed to target the actual biological driver of your tumor. This is where targeted therapies offer a better path. Osimertinib …
